System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Gabriel Etienne is an expert in Hematology at Institut Bergonié (France). As of October 2026, ScienceLeadR ranks Gabriel Etienne in the top 1% of experts worldwide for Leukemia. Gabriel Etienne has authored 248 publications, the most recent in 2026, and is an investigator in 32 clinical trials, 8 of them ongoing. SLR score: 1,107 (community average: 125). How the SLR is computed.

LeadR Profile

Gabriel Etienne Institut Bergonié France
1 107 ScienceLeadR Reputation 1107

Unlock

Register Login
Network Map

Hematology

Subspecialties: Oncology - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1995 - 2026
Source: PubMed

Institut Bergonié

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 248

Citations

Citations: 12 786 1st author: 20 Last author: 25 Unique author: 1

Main journals

Blood 102
Haematologica 11
J Clin Oncol 11
Br J Haematol 10
Leukemia 10

Best Journals

J Clin Oncol 4
N Engl J Med 4
Lancet Oncol 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Development and External Validation of a Transcriptome-Based Multivariable Prediction Model for Treatment-Free Remission in Chronic Myeloid Leukemia.
PMID 42454992 — cells, transcriptome, leukemia, machine learning, leukemia, myeloid, therapeutics, learning, leukemia, myelogenous, chronic, bcr-abl positive		J Clin Oncol Top journal20262
Favorable tolerability of asciminib versus ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia.
PMID 42389818 — hematology, safety, leukemia, leukemia, myeloid, protein-tyrosine kinases, tyrosine, therapeutics, leukemia, myelogenous, chronic, bcr-abl positive		Haematologica20260
Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial.
PMID 42069411 — interferon-alpha, therapeutics, suicide, attempted, suicide		Lancet Haematol20260
ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors.
PMID 42026180 — leukemia, leukemia, myeloid, protein-tyrosine kinases, tyrosine, therapeutics, leukemia, myelogenous, chronic, bcr-abl positive		Leukemia20260
Extended long-term follow-up and the survival of Stop Imatinib study.
PMID 41574312 — survival rate		Blood Neoplasia20250

Clinical Studies 32

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2 Study Chair: 2

By phase:

Phase 3 12
Phase 2 9
N/A 8
Phase 1/Phase 2 2
Phase 1 1

By status:

Completed 17
Recruiting 7
Active not recruiting 3
Terminated 3
Not yet recruiting 1
Unknown 1

By type:

Interventional 28
Observational 4

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 0
multicentric5to9 3
multicentricup10 24

Main Topics

Ongoing Clinical Trials

8 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
CANDIDATE THERAPIES IN COMBINATION OR SEQUENTIALLY WITH TYROSINE KINASE INHIBITORS IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP CML) PATIENTS IN COMPLETE CYTOGENETIC RESPONSE WITHOUT ACHIEVING A DEEP MOLECULAR RESPONSE AN ADAPTIVE TRIAL BASED ON A DROP LOSER DESIGN ACTIW STUDY
2024-516328-32-00 — protein-tyrosine kinases, tyrosine, therapeutics, cytogenetics		Phase 2Not yet recruiting2024
A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor na ve myelofibrosis and moderate thrombocytopenia
2024-511309-47-00 — safety, janus kinase inhibitors, primary myelofibrosis, thrombocytopenia		Phase 2Recruiting2024
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph CML CP
2023-508838-33-00 — multiple chronic conditions, leukemia, respect, leukemia, myeloid, chromosomes, leukemia, myelogenous, chronic, bcr-abl positive, philadelphia chromosome		Phase 3Active not recruiting2021
Value of Biological Age in Addition to Individual Frailty for Personalising the Management of Cancer Treated with Targeted Therapy
NCT06130787 — quality of life, bone marrow, blood, genes, abl, aging, neoplasms, leukemia, dna methylation, leukemia, myeloid, protein-tyrosine kinases, diagnosis, tyrosine, therapeutics, frailty, dna, leukemia, myelogenous, chronic, bcr-abl positive		N/ARecruiting2023
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor na ve Myelofibrosis and Moderate Thrombocytopenia
NCT05980806 — safety, tablets, symptom assessment, janus kinase inhibitors, spleen, primary myelofibrosis, thrombocytopenia		Phase 2Recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS